0000902664-19-003962.txt : 20191010
0000902664-19-003962.hdr.sgml : 20191010
20191010181154
ACCESSION NUMBER: 0000902664-19-003962
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191008
FILED AS OF DATE: 20191010
DATE AS OF CHANGE: 20191010
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON DAVID EDWARD
CENTRAL INDEX KEY: 0001785557
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10865
FILM NUMBER: 191146797
MAIL ADDRESS:
STREET 1: 520 MADISON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000792977
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042742593
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 6174983300
MAIL ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: AMAG PHARMACEUTICALS INC.
DATE OF NAME CHANGE: 20070724
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MAGNETICS INC
DATE OF NAME CHANGE: 19920703
4
1
ownership.xml
X0306
4
2019-10-08
0
0000792977
AMAG PHARMACEUTICALS, INC.
AMAG
0001785557
JOHNSON DAVID EDWARD
520 MADISON AVENUE
NEW YORK
NY
10022
1
0
1
0
Common Stock, par value $0.01 per share ("Common Stock")
2019-10-08
4
A
0
4407
A
4407
D
Common Stock
3499428
I
See footnote
Stock Option (Right to Buy)
11.58
2019-10-08
4
A
0
6000
A
2029-10-08
Common Stock
6000
6000
D
Stock Option (Right to Buy)
11.58
2019-10-08
4
A
0
9452
A
2029-10-08
Common Stock
9452
9452
D
Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in seven equal monthly installments beginning on November 1, 2019; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer.
Not applicable.
Such securities are held by an affiliated fund and managed account to which Caligan Partners LP ("Caligan") serves as investment manager. David Johnson is the Partner of Caligan and Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twenty-four equal monthly installments over two years from the date of grant.
Grant of stock option pursuant to the Plan. This option will vest and become exercisable in seven equal monthly installments commencing November 1, 2019.
Mr. Johnson disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that Mr. Johnson is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
/s/ David Johnson
2019-10-10